Summary
Twelve hypertensive patients (WHO Stage I-II) were given oral verapamil (Isoptin) b.d. or t.d.s. as long-term treatment. The pharmacokinetics of verapamil and norverapamil were studied both after single and b.d. and t.d.s. doses of verapamil 240, 360 or 480 mg daily adjusted according to the blood pressure response. The apparent oral clearance of verapamil was decreased after both the twice and thrice daily dosage regimens (1.38 and 1.841/min, respectively) as compared to the single dose (4.39 l/min). The plasma half-life of verapamil was increased from 3.34 h (single dose) to 4.65 h (b.i.d.). Decreased elimination of norverapamil was also found after multiple doses of verapamil, as shown by an increase in the adjusted AUC of norverapamil (adjusted to a verapamil dose of 80 mg), namely from 574.9 h·ng·ml−1 (single dose) to 1172 h·ng·ml−1 (b.d.) and to 841 h·ng·ml−1 (t.d.s.). The plasma half-life of norverapamil increase from 5.68 h to 7.34 h during twice daily dosing. During thrice daily verapamil, no increase in plasma half-life was found either for verapamil or norverapamil, probably due to the relatively short sampling time (6 h). The plasma concentration of verapamil and the reduction in supine systolic and diastolic blood pressure were correlated. The mean decrease in supine systolic blood pressure was 5.8 mm Hg per 100 ng verapamil/ml plasma, and for diastolic pressure 2.9 mm Hg per 100 ng verapamil/ml plasma. The mean steadystate plasma concentrations of verapamil were similar after twice and thrice daily dosing regimens, which agrees with the clinical observation that blood pressure control in hypertensive patients is as good after verapamil b.d. and t.d.s.
Similar content being viewed by others
References
McAllister RG Jr, Kirsten EB (1982) The pharmacology of verapamil IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31: 418–426
Anavekar SN, Christophidis N, Louis WJ, Doyle AE (1981) Verapamil in the treatment of hypertension. J Cardiovasc Pharmacol 3: 287–292
Anderson P (1986) Pharmacokinetics of calcium channel blocking agents. Acta Pharmacol Toxicol 58 [Suppl II]: 43–57
Anderson P, Bondesson U, Sylven C (1982a) Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. Eur J Clin Pharmacol 23: 49–57
Anderson P, Bondesson U, Sylven C, Åström H (1982b) Plasma concentration-response relationship of verapamil in the treatment of angina pectoris. J Cardiovasc Pharmacol 4: 609–614
Eichelbaum M, Dengler HJ, Somogyi A, von Unruh GE (1981a) Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Eur J Clin Pharmacol 19: 127–131
Eichelbaum M, Mikus G, Vogelgesang B (1984) Pharmacokinetics of (+)↑-, (−)↓- and (+/−)-verapamil after intravenous administration. Br J Clin Pharmacol 17: 453–458
Eichelbaum M, Somogyi A (1984) Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Eur J Clin Pharmacol 26: 47–53
Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1981b) Simultaneous determination of the intravenous and oral pharmacokinetic parameters ofD, L-verapamil using stable isotopelabelled verapamil. Eur J Clin Pharmacol 19: 133–137
Freedman SB, Richmond DR, Ashley JJ, Kelly DT (1981) Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther 30: 644–652
Gould BA, Mann S, Kieso H, Bala Subramanian V, Raftery EB (1982) The 24-hour intraarterial ambulatory profile of blood pressure reduction with verapamil. Circulation 65: 22–27
Halperin AK, Gross KM, Rogers JF, Cubeddu LX (1984) Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther 36: 750–758
Hedbäck B, Hermann L Sparre (1984) Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension. Acta Med Scand 681: [Suppl] 129–134
Johnston A, Burgess CD, Hamer J (1981) Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol 12: 397–400
Kates RE, Keefe DLD, Schwartz J, Harapat S, Kirsten EB, Harrison DC (1981) Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther 30: 44–51
Leary WP, Phil D, Asmal AC (1979) Treatment of hypertension with verapamil. Curr Ther Res 25: 747–752
Leonetti G, Sala C, Bianchini C, Tezoli L, Zanchetti A (1980) Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol 18: 375–382
Lewis GRJ, Morley KD, Lewis BM, Bones PJ (1978) The treatment of hypertension with verapamil. N Z Med J 87: 351–354
Midtbö K, Hals O (1980) Verapamil in the treatment of hypertension. Curr Ther Res 27: 830–838
Neugebauer G (1978) Comparative cardiovascular actions of verapamil and its major metabolites in anaesthetised dog. Cardiovasc Res 12: 247–254
Reiter MJ, Shand DG, Pritchett ELC (1982) Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther 32: 711–720
Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10: 605–612
Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC (1982) Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J 104: 198–203
Semplicini A, Pessina AC, Rossi GP, Padrini R, Tagliafierro R, Quintarelli GF, Ferrari M, Dal Palu C (1982) Plasma levels of verapamil and its effects on blood pressure, body fluid volumes and renal function in hypertensive patients. Int J Clin Pharm Res 2 [Suppl 1]: 81–86
Shand DB, Hammill SC, Aanonsen L, Pritchett ELC (1981) Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther 30: 701–703
Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M (1981) Pharamcokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 12: 51–60
Storstein L, Midtbö K, Hals O, Myhre E (1981) Antihypertensive effect of verapamil in relation to plasma concentrations of verapamil and its active metabolite norverapamil. Curr Ther Res 29: 112–119
Wagner JG, Rocchini AP, Vasiliades J (1982) Prediction of steadystate verapamil plasma concentrations in children and adults. Clin Pharmacol Ther 32: 172–181
Woodcock BG, Rietbrock I, Vöhringer HF, Rietbrock N (1981) Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther 29: 27–34
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anderson, P., Bondesson, U. & de Faire, U. Pharmacokinetics of verapamil in patients with hypertension. Eur J Clin Pharmacol 31, 155–163 (1986). https://doi.org/10.1007/BF00606652
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606652